Japan Cancer Vaccines Market Growth, Size, Trends, Demand, Price, Challenges and Future Outlook

Japan Cancer Vaccines Market Size- By Vaccine Type, By Indication, By Patient Type- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Japan Cancer Vaccines Market Size- By Vaccine Type, By Indication, By Patient Type- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Published: May 2023 Report ID: HLCA2333 Pages: 1 - 104 Formats*:     
Category : Healthcare
Japan Cancer Vaccines Market Overview

According to SPER Market Research, the Japan Cancer Vaccines Market is estimated to reach USD 4.68 billion by 2033 with a CAGR 18.04%.

The cancer vaccine market is a part of the healthcare industry that focuses on developing vaccines to prevent or treat cancer. Cancer is a disease in which cells in the body grow uncontrollably and can spread to other parts of the body. Cancer vaccines aim to activate the immune system to target and eliminate cancer cells. These vaccines work by either preventing cancer from developing or by treating an existing cancer by slowing its growth or killing cancer cells. The market includes various stakeholders, such as pharmaceutical and biotechnology companies, government agencies, cancer treatment centres, research institutes, investors, patients, and advocacy groups. The ultimate goal of the cancer vaccine market is to provide safe and effective vaccines that can help prevent and treat cancer, improve patient outcomes, and reduce the burden of cancer on society.

Exploring the Growth Drivers of the Japan Cancer Vaccines Industry

The Japan cancer vaccines industry is expected to grow rapidly in the coming years, driven by several factors. One of the major growth drivers is the increasing prevalence of cancer in the country. As the population ages and lifestyles change, the incidence of cancer is expected to rise, creating a greater demand for cancer vaccines. Another growth driver is the supportive regulatory environment in Japan. The Japanese government has been actively promoting the development of new cancer vaccines, providing financial support and regulatory incentives to companies that are working on these products. This has helped to stimulate innovation and investment in the industry, and has made Japan a hub for cancer vaccine research and development. 
Japan Cancer Vaccines Market
What challenges does the Japan Cancer Vaccines Market face?
Despite the opportunities for growth, the Japan cancer vaccines market also faces several challenges. One of the major challenges is the high cost of developing and producing cancer vaccines. The process of developing and testing vaccines can be expensive and time-consuming, which can make it difficult for smaller companies to compete in the market. Another challenge is the regulatory landscape in Japan, which can be complex and difficult to navigate. Companies that are developing cancer vaccines must meet strict regulatory requirements and obtain approvals from government agencies, which can be a lengthy and expensive process.

In what ways has the COVID-19 pandemic affected Japan Cancer Vaccines Market?
The COVID-19 pandemic has had a significant impact on the Japan cancer vaccines industry. One of the immediate effects of the pandemic was a disruption in clinical trials, as many hospitals and research centres were closed or diverted their resources to COVID-19 response efforts. This has led to delays in the development and approval of cancer vaccines in Japan. In addition, the pandemic has also caused a shift in priorities and resources, with many companies and research organizations focusing on COVID-19-related research and development. This has led to a reduction in funding and attention for other areas of healthcare, including cancer vaccines.

Japan Cancer Vaccines Market


Scope of the Report:
 Report Metric Details
 Market size available for years 2019-2033
 Base year considered 2022
 Forecast period 2023-2033
 Segments coveredBy Vaccine Type, By Indication, By Patient Type
 Regions coveredTokyo, Kyoto, Osaka, Yokohama, Kobe, Others
 Companies CoveredAduro BioTech Inc., Astellas Pharma Inc., Bristol-Myers Squibb, CYTLIMIC, Oncolys BioPharma Inc., Takara Bio, Takeda Pharmaceutical, tella Inc.
Key Target Audience:
  • Pharmaceutical and Biotechnology Companies
  • Cancer Treatment Centres and Hospitals
  • Patients and Caregivers
  • Research Institutes
Japan Cancer Vaccines Market Segmentation:
1. By Vaccine Type:
  • Japan Cancer Vaccines Market Value Share and Forecast, By Vaccine Type, 2023-2033
  • Prevention Vaccines
  • Treatment Vaccines
  • Oncolytic Viruses
2. By Indication:
  • Japan Cancer Vaccines Market Value Share and Forecast, By Indication, 2023-2033
  • Prostate Cancer
  • Cervical Cancer
  • Others
3. By Patient Type:
  • Japan Cancer Vaccines Market Value Share and Forecast, By Patient Type, 2023-2033
  • Paediatric
  • Adult
4. By Region:
  • Tokyo
  • Kyoto
  • Osaka
  • Yokohama
  • Kobe
  • Others
Key Topics Covered in the Report:
  • Japan Cancer Vaccines Market Size (FY’2023-FY’2033)
  • Overview of Japan Cancer Vaccines Market 
  • Segmentation of Japan Cancer Vaccines Market By Vaccines Type (Prevention Vaccines, Treatment Vaccines, Oncolytic Viruses)
  • Segmentation of Japan Cancer Vaccines Market By Indication (Prostate Cancer, Cervical Cancer, Other)
  • Segmentation of Japan Cancer Vaccines Market By Patient Type (Paediatric, Adult)
  • Statistical Snap of Japan Cancer Vaccines Market 
  • Growth Analysis of Japan Cancer Vaccines Market 
  • Problems and Challenges in Japan Cancer Vaccines Market 
  • Competitive Landscape in the Japan Cancer Vaccines Market 
  • Impact of COVID-19 and Demonetization on Japan Cancer Vaccines Market 
  • Details on Recent Investment in Japan Cancer Vaccines Market 
  • Competitive Analysis of Japan Cancer Vaccines Market 
  • Key Players in the Japan Cancer Vaccines Market 
  • SWOT Analysis of Japan Cancer Vaccines Market 
  • Japan Cancer Vaccines Market Future Outlook and Projections (FY’2023-FY’2033)
  • Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan Cancer Vaccines Market

5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces 
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape
6.1. Japan Cancer Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type 
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cancer Vaccines Market

7. Japan Cancer Vaccines Market, By Vaccine Type (USD Million)
7.1. Japan Cancer Vaccines Market Value Share and Forecast, By Vaccine Type, 2023-2033
7.2. Prevention Vaccines
7.2.1. HPV
7.2.2. HBV
7.3. Treatment Vaccines
7.3.1. Antigen vaccines
7.3.2. Dendritic cell vaccines
7.3.3. DNA vaccines
7.3.4. Whole tumor vaccines
7.3.5. Anti-idiotype vaccines
7.4. Oncolytic Viruses

8. Japan Cancer Vaccines Market, By Indication (USD Million)
8.1. Japan Cancer Vaccines Market Value Share and Forecast, By Indication, 2023-2033
8.2. Prostate Cancer
8.3. Cervical Cancer
8.4. Others

9. Japan Cancer Vaccines Market, By Patient Type (USD Million)
9.1. Japan Cancer Vaccines Market Value Share and Forecast, By Patient Type, 2023-2033
9.2. Paediatric
9.3. Adult

10. Japan Cancer Vaccines Market Forecast, 2019-2033 (USD Million)
10.1. Japan Cancer Vaccines Market Size and Market Share

11. Japan Cancer Vaccines Market, By Vaccine Type, 2019-2033 (USD Million)
11.1. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2019-2026)
11.2. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2027-2033)

12. Japan Cancer Vaccines Market, By Indication, 2019-2033 (USD Million)
12.1. Japan Cancer Vaccines Market Size and Market Share by Indication (2019-2026)
12.2. Japan Cancer Vaccines Market Size and Market Share by Indication (2027-2033)

13. Japan Cancer Vaccines Market, By Patient Type, 2019-2033 (USD Million)
13.1. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2019-2026)
13.2. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2027-2033)

14. Japan Cancer Vaccines Market, By Region, 2019-2033 (USD Million)
14.1. Japan Cancer Vaccines Market Size and Market Share by Region (2019-2026)
14.2. Japan Cancer Vaccines Market Size and Market Share by Region (2027-2033)
14.3. Tokyo
14.4. Kyoto
14.5. Osaka
14.6. Yokohama
14.7. Kobe
14.8. Others

15. Company Profile
15.1. Aduro BioTech Inc.
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary 
15.1.4. Recent developments
15.2. Astellas Pharma Inc.
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary 
15.2.4. Recent developments
15.3. Bristol-Myers Squibb
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary 
15.3.4. Recent developments
15.4. CYTLIMIC
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary 
15.4.4. Recent developments
15.5. Oncolys BioPharma Inc.
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary 
15.5.4. Recent developments
15.6. Takara Bio
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary 
15.6.4. Recent developments
15.7. Takeda Pharmaceutical
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary 
15.7.4. Recent developments
15.8. tella Inc
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary 
15.8.4. Recent developments

16. List of Abbreviations

17. Reference Links

18. Conclusion

19. Research Scope

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3


Frequently Asked Questions About This Report
Japan Cancer Vaccines Market is projected to reach USD 4.68 billion by 2033, growing at a CAGR of 18.04% during the forecast period.
Japan Cancer Vaccines Market grew in market size from 2022. The Market is expected to reach USD 4.68 billion by 2033, at a CAGR of 18.04% during the forecast period.
Japan Cancer Vaccines Market CAGR of 18.04% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Japan Cancer Vaccines Market size is USD 4.68 billion from 2023 to 2033.
Japan Cancer Vaccines Market Segment is covered By Vaccine Type, By Indication, By Patient Type.
The Asia-Pacific region is anticipated to have the highest market share in the Japan Cancer Vaccines Market.
The key players in the market include Companies Covered Aduro BioTech Inc., Astellas Pharma Inc., Bristol-Myers Squibb, CYTLIMIC, Oncolys BioPharma Inc., Takara Bio, Takeda Pharmaceutical, tella Inc.
Cancer vaccines aim to activate the immune system to target and eliminate cancer cells. These vaccines work by either preventing cancer from developing or by treating an existing cancer by slowing its growth or killing cancer cells.
Not able to find what you are looking for? Need customization in the existing report?
Click Here
PLACE AN ORDER
  • 15% off
     
    $ 2950
  • 20% off
             
    $ 3950
  • 25% off
         
    $ 5150
Pre-Purchase Inquiry
SEND AN INQUIRY
NEED CUSTOMIZATION?
Request Customization
CALL OR EMAIL US
US:
India:
Email:
100% Secure Payment

SPER American Express
SPER VISA
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-PWC
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Microsoft
SPER-EY
SPER-Sanofi
SPER-p&g
SPER-Johnson & Johnson
SPER-SIEMENS
SPER-LOREAL
SPER-Pfizer
SPER-IPSOS
SPER-Heineken
SPER-IQVIA
SPER-Kankar IMRB
SPER-PWC

SPER

Market Research

We are the leading, full-service global market research and consulting company.

Certificates
iso-1 iso-1 iso-1 ESOMAR
Secure Payments
SPER Payment Options
Contact HR

 [email protected]

 +91-742-898-5650